With more than 25 years of experience in management positions in the pharmaceutical industry (HMR, now Sanofi), Dr. Dominique Costantini has overseen many therapeutic innovations and was involved in the development of numerous medicines, from conception to product approval and commercialisation (notably in immunology, oncology, endocrinology and infectious illnesses).
In 1997, Dominique Costantini founded and led as CEO BioAlliance Pharma (now Onxeo), a biotech company in oncology and supportive care; in 2005, she conducted the company’s IPO on Euronext and the registration of products in Europe and the US.
In 2012, Dominique founded and was CEO of OSE Pharma, a biotech company in cancer immunotherapy. In 2015, she conducted the company’s IPO on Euronext and in 2016 its merger with Effimune, a biotechnology company specialized in immune regulation, to create OSE Immunotherapeutics.
Dominique serves as Chairman and Director of development of OSE Immunotherapeutics.
Dr. Dominique Costantini is a Medical Doctor (Paris V University), specializing in immunology.